首页
数据库
关于我们
联系我们
您当前的位置： 首页 > 数据库
所属年份
2008 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
到
2008 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
检索 清除
手术分类
  • 全部（2447）
  • 腹部手术（342）
  • 胸科手术（70）
  • 血管手术（5）
  • 心脏手术（97）
  • 神经外科（4）
  • 头颈部（35）
  • 骨科（78）
  • 泌尿外科（0）
  • 妇产手术（77）
  • 日间手术（26）
  • 手术室外（28）
  • 创伤和烧伤（0）
  • 非心脏手术（472）
  • 老年（0）
  • 小儿新生儿（189）
  • 特殊患者（42）
  • 未说明手术类型（982）
阶段管理
  • 术前宣教（21）
  • 术前评估（33）
  • 术前用药（15）
  • 术前禁食水（12）
  • 麻醉选择（21）
  • 麻醉用药（10）
  • 术中监测（23）
  • 液体管理（14）
  • 血液保护（3）
  • 体温管理（8）
  • 术后疼痛（62）
  • POD（8）
  • PONV（10）
  • 术后康复（50）
  • 特殊情况（43）
  • 术前肠道准备（9）
排序：
发表时间 阅读量
Array ( [id] => 3165 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3165.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block. [laiyuan] => 神经轴阻滞或深丛 / 外周阻滞前，阿哌沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
神经轴阻滞或深丛 / 外周阻滞前，阿哌沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3166 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3166.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first postoperative dose (high dose). [laiyuan] => 高剂量给阿哌沙班场景下，穿刺/拔管应在术后首次给药前至少24小时进行。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
高剂量给阿哌沙班场景下，穿刺/拔管应在术后首次给药前至少24小时进行。（证据等级：低，推荐强度：弱推荐）

We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first postoperative dose (high dose).

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3167 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3167.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => With the unanticipated administration of high dose of apixaban with a neuraxial catheter in situ, we suggest that apixaban dosing be withheld for at least 72 hours, or a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed. [laiyuan] => 若神经轴导管在位时意外使用了高剂量阿哌沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
若神经轴导管在位时意外使用了高剂量阿哌沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐）

With the unanticipated administration of high dose of apixaban with a neuraxial catheter in situ, we suggest that apixaban dosing be withheld for at least 72 hours, or a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3168 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3168.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a low dose of apixaban be discontinued for at least 36 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking apixaban or aXa plasma level if <36 hours. [laiyuan] => 建议低剂量阿哌沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 36 小时；若停药时间不足 36 小时，可考虑检测阿哌沙班或抗 Xa 因子血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
建议低剂量阿哌沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 36 小时；若停药时间不足 36 小时，可考虑检测阿哌沙班或抗 Xa 因子血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a low dose of apixaban be discontinued for at least 36 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking apixaban or aXa plasma level if <36 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3169 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3169.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that needle placement/catheter removal occurs at least 6 hours prior to the first postoperative dose (low dose). [laiyuan] => 低剂量给阿哌沙班场景下，穿刺 / 拔管应在术后首次给药前至少 6 小时进行。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
低剂量给阿哌沙班场景下，穿刺 / 拔管应在术后首次给药前至少 6 小时进行。（证据等级：低，推荐强度：弱推荐）

We suggest that needle placement/catheter removal occurs at least 6 hours prior to the first postoperative dose (low dose).

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3170 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3170.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => With the unanticipated administration of low dose of apixaban with a neuraxial catheter in situ, we suggest that apixaban dosing be withheld for at least 36 hours, or a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed. [laiyuan] => 若神经轴导管在位时意外使用了低剂量阿哌沙班，建议停药至少 36 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
若神经轴导管在位时意外使用了低剂量阿哌沙班，建议停药至少 36 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐）

With the unanticipated administration of low dose of apixaban with a neuraxial catheter in situ, we suggest that apixaban dosing be withheld for at least 36 hours, or a residual apixaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3171 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3171.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a high dose of edoxaban be discontinued for at least 72 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking edoxaban or aXa activity plasma level if <72 hours. [laiyuan] => 建议高剂量依度沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测依度沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
建议高剂量依度沙班在神经轴阻滞或深丛 / 外周阻滞前至少停药 72 小时；若停药时间不足 72 小时，可考虑检测依度沙班或抗 Xa 因子活性血浆水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a high dose of edoxaban be discontinued for at least 72 hours prior to neuraxial block or deep plexus/peripheral block. Consider checking edoxaban or aXa activity plasma level if <72 hours.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3172 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3172.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that a residual edoxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block. [laiyuan] => 神经轴阻滞或深丛 / 外周阻滞前，依度沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
神经轴阻滞或深丛 / 外周阻滞前，依度沙班残余血浆水平 < 30 ng/mL 或残余抗 Xa 因子活性≤0.1 IU/mL 为可接受水平。（证据等级：低，推荐强度：弱推荐）

We suggest that a residual edoxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL is acceptable prior to neuraxial block or deep plexus/peripheral block.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3173 [catid] => 289 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3173.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first (postoperative) dose (high dose). [laiyuan] => 高剂量给依度沙班场景下，穿刺 / 拔管应在（术后）首次给药前至少 24 小时进行。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
高剂量给依度沙班场景下，穿刺 / 拔管应在（术后）首次给药前至少 24 小时进行。（证据等级：低，推荐强度：弱推荐）

We suggest that needle placement/catheter removal occurs at least 24 hours prior to the first (postoperative) dose (high dose).

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读
Array ( [id] => 3174 [catid] => 303 [title] => Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition) [thumb] => [keywords] => [description] => [hits] => [uid] => 3 [author] => 甘肃中医院 [status] => 9 [url] => /show/3174.html [link_id] => 0 [tableid] => 0 [inputip] => 106.86.177.165 [inputtime] => 2026-04-14 11:42:49 [updatetime] => 2026-04-14 11:42:49 [displayorder] => 0 [nrjc] => Array ( ) [nrsh] => Array ( ) [xzl] => 0 [dzl] => 0 [wailian] => https://www.ipubmed.cn/Archive/Detail/39880411 [demo_url] => [zjpjff] => GRADE [zjfj] => [tjqd] => [nianfen] => 2025 [guojia] => American Society of Regional Anesthesia & Pain Med [pdf] => [tjyjyw] => [lyyw] => With the unanticipated administration of high dose of edoxaban with a neuraxial catheter in situ, we suggest that edoxaban dosing be withheld for at least 72 hours, or a residual edoxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed. [laiyuan] => 若神经轴导管在位时意外使用了高剂量依度沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐） [znzldj] => B [_inputtime] => 1776138169 [_updatetime] => 1776138169 [_nrjc] => [_nrsh] => )
推荐意见
若神经轴导管在位时意外使用了高剂量依度沙班，建议停药至少 72 小时，或检测残余血浆水平 < 30 ng/mL、残余抗 Xa 因子活性≤0.1 IU/mL 后再拔管。（证据等级：低，推荐强度：弱推荐）

With the unanticipated administration of high dose of edoxaban with a neuraxial catheter in situ, we suggest that edoxaban dosing be withheld for at least 72 hours, or a residual edoxaban plasma level <30 ng/mL or a residual aXa activity plasma level ≤0.1 IU/mL before the catheter is removed.

证据评价方法：GRADE

指南质量等级：B

年份：2025

国家：American Society of Regional Anesthesia & Pain Med

来源 Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (fifth edition)
原文链接
阅读

地址：甘肃省兰州市七里河区瓜州路418号

邮编：730050

电话：0931-2687109

商务合作热线：0931-2687106

备案号：陇ICP备17005383号-1 联网备案号：62010302000288

技术支持：瑞秀科技